Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30928268 | 0.85 | KMT2A (0.55) | KMT2AMEN1NPC1NPY1RALDH1A1 | |
| SCHEMBL6052931 | 0.82 | KMT2A (0.43) | KMT2AMEN1NPC1NPY1RALDH1A1 | |
| SCHEMBL2062279 | 0.82 | KMT2A (0.43) | KMT2AMEN1NPC1NPY1RALDH1A1 | |
| SCHEMBL28105323 | 0.82 | KMT2A (0.43) | KMT2AMEN1NPC1NPY1RALDH1A1 | |
| SCHEMBL29290020 | 0.82 | KMT2A (0.43) | KMT2AMEN1NPC1NPY1RALDH1A1 | |
| SCHEMBL457277 | 0.80 | KMT2A (0.53) | KMT2AMEN1ALDH1A1TDP1CA1 | |
| SCHEMBL9763798 | 0.80 | HSP90AA1 (0.42) | KMT2AMEN1NPY1RALDH1A1TDP1 | |
| SCHEMBL31294204 | 0.80 | KMT2A (0.53) | KMT2AMEN1ALDH1A1TDP1CA1 | |
| SCHEMBL30267714 | 0.79 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TDP1CA1 | |
| SCHEMBL21834662 | 0.79 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3404017-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| US-7393849-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7323457-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070191347-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. | 2007-08-16 | — | — | US | disclosed |
| US-7223763-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1423373-B1 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| US-6777577-B2 | ANTICANCER AGENTS; ANTIDIABETIC AGENTS, ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS, OSTEOPOROSIS | AVENTIS PHARMACEUTICALS INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1423373-A2 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | Aventis Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | ARIAD PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2003006444-A2 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | KMT2A 1622/4885MEN1 755/4885NPC1 46/4885 |
| US-20070208008-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | CHUK, SRC, DSTYK | KMT2A 1067/4885MEN1 4554/4885NPC1 4486/4885 |
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | CHUK, SRC, DSTYK | KMT2A 1104/4885MEN1 4490/4885NPC1 4422/4885 |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | SRC, GRB2, ACP1 | KMT2A 1735/4885MEN1 3737/4885NPC1 4321/4885 |
| US-20070191347-A1 | SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | CHUK, SRC, DSTYK | KMT2A 1067/4885MEN1 4554/4885NPC1 4486/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | KMT2A 1622/4885MEN1 755/4885NPC1 46/4885 |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | SRC, CHUK, DSTYK | KMT2A 693/4885MEN1 4371/4885NPC1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.